Supported by an educational grant from Axsome Therapeutics, Inc.

Homepage

Featured

Education
Breaking the Monoamine Barrier - The Limits of Monoamines: Why Conventional Antidepressants Fall Short (Module 1)
See More
Videos
MOA Animation: Modulating Glutamate, Inflammation, and Neuroplasticity in Major Depressive Disorder

Faculty

Craig Chepke, MD, DFAPA
Medical Director,
Excel Psychiatric Associates
Rakesh Jain, MD, MPH
Clinical Professor,
Texas Tech - Permian Basin
Desiree Matthews, PMHNP-BC
CEO,
Different MHP, PC
Kristian Dambrino, MSN, APRN, PMHNP-BC
Founder, Psychiatric Nurse Practitioner,
Dambrino Consulting & Wellness LLC
Lara Shirikjian, DO
Principal Investigator,
Medical Director,
Cenexel CNS
Brooke Kempf, PMHNP-BC
Adjunct Faculty,
Indiana University Indianapolis

Microlearning

Education
Breaking the Monoamine Barrier - The Limits of Monoamines: Why Conventional Antidepressants Fall Short (Module 1)

This first module in the series of Breaking the Monoamine Barrier will focus on describing the limitations of conventional monoaminergic antidepressants that are associated with subop

Education
Breaking the Monoamine Barrier - Beyond Serotonin: The Role of the Glutamatergic System in MDD (Module 2)

In Module 2 of Breaking the Monoamine Barrier, Dr.

Education

View all
Breaking the Monoamine Barrier - Personalizing Treatment: Strategies for Incorporating Glutamatergic Therapy (Module 4)
Breaking the Monoamine Barrier - Glutamatergic Antidepressants in Practice: When and How to Use Them (Module 3)

Videos

View all
Surmounting Challenges in the Treatment of MDD: A Light at the End of the Tunnel
Evolving Perspectives on Depression: Chronic vs. Episodic Treatment in MDD and the Role of the GABA System
Neuroplasticity and Its Role in MDD: New Solutions with Digital Therapeutics

Podcasts

View all
Why Do Side Effects Lead to Non-Adherence in MDD Treatment?
Ketamine for Depression: Why Does It Work So Fast?
The Role of Astrocytes in Depression: More Than Just Brain Support Cells

News

View all
Pharmacogenomic Test Improves MDD Response and Remission Outcomes
High Levels of THC in Cannabis Products Associated With Mental Health Risks
FDA Approves TMS Device for Major Depressive Disorder in Adolescents

Posters

View all
Characterization of Care Patterns for Patients Newly Diagnosed With Major Depressive Disorder (MDD) in Primary Care Settings: a Retrospective Observational Cohort Study
Association between Anhedonia Severity and Clinical and Humanistic Outcomes Among US Adults with Major Depressive Disorder
Effectiveness of Vortioxetine in Elderly Patients With Major Depressive Disorder in Real-World Clinical Practice: Results From the RELIEVE Study